GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Additional Paid-In Capital

Contineum Therapeutics (Contineum Therapeutics) Additional Paid-In Capital : $7.99 Mil(As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Additional Paid-In Capital?


Contineum Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($6.31 Mil) to Dec. 2023 ($7.10 Mil) and increased from Dec. 2023 ($7.10 Mil) to Mar. 2024 ($7.99 Mil).

Contineum Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($2.74 Mil) to Dec. 2022 ($4.73 Mil) and increased from Dec. 2022 ($4.73 Mil) to Dec. 2023 ($7.10 Mil).

Contineum Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Contineum Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Additional Paid-In Capital Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
2.74 4.73 7.10

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 4.73 - 6.31 7.10 7.99

Contineum Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Contineum Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024